Introduction
Antiretroviral treatment interruptions have been introduced in the course of the antiretroviral treatment of HIV infected patients based on the recent recognition that virus eradication is no longer achievable [1] and because of the issues associated with long-term treatment with highly active antiretroviral therapy (HAART) such as compliance, side effects and drug resistance [2, 3] . In addition, on the sole basis of immune system physiology, some authors have argued that treatment interruption might result in a stimulation of the immune system against HIV [4] [5] [6] [7] . As a result, partial or complete antiretroviral treatment interruption has been evaluated in chronically infected patients or during primo-infection [4, [8] [9] [10] [11] [12] [13] [14] [15] [16] . On the whole, available data on the kinetics of immune markers in the context of long-term antiretroviral treatment interruption in chronically infected patients are still scarce. A better understanding of the immune response in this situation might, nevertheless, help (1) to evaluate the consequences and the indications for treatment interruption in clinical practice, and (2) to evaluate the status of the immune system in chronically infected patients who have been treated for several years. Recently, some reports have focused on the key role of dendritic cells (DC) in HIV pathogenesis. Owing to their central role in the immune system, these cells have been implicated in the dissemination of the infection [17] but have also been associated with long-term nonprogression [18] . Such cells may play a role in the control of viral replication [19] through the secretion of type 1 Interferon (lymphoid DC) [20] and in the modulation of T-cell response after treatment interruption. Thus, we included longitudinal monitoring of peripheral blood DC subsets including myeloid DCs and lymphoid DCs.
The aim of the present study was to analyse specific immunological markers in addition to classical determinants associated with the changes in the CD4þ cell count during a 12-month follow-up period after treatment discontinuation to better define those patients who were eligible for treatment cessation and for whom this strategy is as safe as possible.
Methods
Design and data collection Patients referred to the participating clinical unit (G2, Haut-Lévêque Hospital, Bordeaux, France) and for whom a discontinuation of their antiretroviral therapy with a CD4þ count level above 400 Â 10 6 cells/l and CD4þ T cell percentage (%) > 20% were included in the cohort upon their agreement. Treatment was interrupted because of side effects, personal convenience or because HAART would not have been started based on today's more conservative guidelines. The primary care provider made decisions regarding when to resume therapy. After treatment interruption, data were recorded prospectively during scheduled visits at 1 month (M1), M3, M6, M9 and M12. Other information was provided through the Aquitaine Cohort database as all patients participated in this cohort [21] . In short, the Aquitaine Cohort is a prospective hospital-based cohort of HIV-1 infected patients under routine clinical management initiated in 1987 in Bordeaux University Hospital and four other public hospitals in Aquitaine, South-western France. Clinical, biological and therapeutic information were collected prospectively at each visit.
Phenotypic analysis of white blood cells in peripheral blood from patients
Peripheral blood samples for analysis were collected on ethylenediamine tetra-acetic acid and processed within the following 5 h. Whole blood aliquots (0.1 ml) were incubated with the monoclonal antibody mixture (0.02) for 15 min. Fluorescence-activated cell sorter (FACS) lysing solution from BD Sciences (BD Sciences, Pont de Claix, France) was then added for another 10 min before the cells were analysed in the FACSCalibur (BD Sciences). Total lymphocyte gating was set up on physical parameters as well as on CD45 to prevent inclusion of red blood cells in the lymphocyte gate. A minimum of 5000 total lymphocytes were taken into account for each test. The following combinations of monoclonal antibodies were utilized for the phenotypic analysis: CD45/CD3/ CD4/CD8, CD45/CD3/HLA-DR, CD3/CD4/CD8/ HLA-DR, Lineages þ/CD11C/CD123/HLA-DR. Results were expressed as percentages of positive cells among total lymphocytes and as absolute counts obtained with the True count kit (BD Sciences) in cell numbers Â 10 6 /l, except for dendritic cells whose numbers were expressed per millilitre of blood.
Statistical methods
The kinetics of the CD4þ cell count and the HIV RNA viral load were estimated using a piecewise linear mixed model taking into account the correlation between repeated measurements in the same patient [22] . Baseline was defined as the time of treatment interruption. Data were censored from the time of treatment resumption or from the last available follow-up (most often 12 months). The model was used to estimate the baseline level at the time of treatment interruption, the first slope during the first month and the second slope thereafter. The time point of slope change was the time that led to the best model (i.e. highest likelihood) thus providing the estimated values closest to observed ones. The effect of covariates (measured at M0 or M1) on baseline and on the two slopes was tested by a Wald test for interactions. A multivariable model including all significant variables in unadjusted analyses was performed. The model also allowed for the estimation of the correlation between individual baseline, first slope and second slope through the random effects correlation matrix. The joint kinetic of markers (CD4, CD8, CD8 DRþ, HIV RNA, dendritic cells) during the first month was studied by calculating the Pearson correlation between observed slopes at one month. When adapted, the continuous variables were categorized according to their distribution (median and quartiles). For HIV RNA, results on the continuous scale were fitted by imputing 1.4 log 10 copies/ml for undetectable values (i.e. log 10 (50/2) copies/ ml). Results were similar using a multiple imputation approach to take into account undetectable values (data not shown).
The time to resumption of treatment was censored at 12 months if the patient did not resume therapy. The association between this delay and several characteristics was tested using a log-rank test. Strata were defined for each continuous variable according to the tertiles of its distribution. Analyses were performed using SAS software, version 8.2 (SAS Institute, Inc., Cary, North Carolina, USA). Table 1 . The median number of measurements of the following immunological markers: CD4þ, CD8þ, CD4 DRþ, CD8 DRþ, dendritic cells and HIV RNA was five per patient (IQR, 4-6).
Results

Study population
CD4R T-lymphocyte kinetics
At baseline, the CD4þ T-lymphocyte median count was 734 Â 10 6 cells/l (IQR, 584-962). At M1 (1 month after baseline) it decreased to 662 Â 10 6 cells/l (IQR, 494-797), and at M12 (12 months after baseline) to 455 Â 10 6 cells/l (IQR, 352-644) ( Table 2 ). These biphasic changes in the CD4þ T-lymphocyte count after treatment cessation was well represented by a two-slope model (Fig. 1 ). The estimation of the first mean slope in the first month was À142 Â 10 6 cells/l per month [95% confidence interval (CI), À205 to À79] and the estimation of the second slope was À17 Â 10 6 cells/l per month (95% CI, À22 to À12). The CD4þ T-lymphocyte level at baseline was significantly negatively correlated with the first slope (r ¼ À0.63, P < 10 À2 ): the higher the CD4þ T-lymphocyte baseline level was, the steeper the CD4þ T-lymphocyte count decline during the first month. The second slope was not correlated either with baseline level (P ¼ 0.38) or with the first slope (P ¼ 0.29).
Effect of CD4R nadir
The CD4þ T-lymphocyte nadir before treatment interruption was significantly associated with the CD4þ T-lymphocyte kinetic after treatment termination ( Table 3 ). The lower the nadir was, the steeper the CD4þ decline during the first month (À4.6 cells/month per 10 cells lower, P ¼ 0.02). The influence of the CD4þ T-lymphocyte nadir on CD4þ kinetic after antiretroviral treatment interruption was best described in relation to a threshold of 350 Â 10 6 cells/l (median, Table 1 ) rather than on a continuous scale (model log-likelihood À1709 and À1716, respectively; the higher value being better). At the time of treatment interruption, patients with a history of CD4þ T-lymphocyte nadir of less than or above 350 Â 10 6 cells/l had similar CD4þ T-lymphocyte counts (P ¼ 0.56, Table 3 ). However, this nadir threshold led to the delineation of two different behaviours in the first month following treatment interruption since, in patients with a nadir below 350 Â 10 6 cells/l,the CD4þ T-lymphocyte count decline was steeper leading to a mean level of 561 Â 10 6 cells/l (95% CI, 485-636) at M1 and 366 Â 10 6 cells/l (95% CI, 297-434) at M12 in comparison with 740 Â 10 6 cells/l (95% CI, 660-819) and 539 Â 10 6 cells/l (95% CI, 471-607), respectively, for patients with a nadir above 350 Â 10 6 cells/l ( Fig. 2a ). This effect of nadir CD4þ T-lymphocytes was independent of baseline HIV RNA viral load as its effects remained even after adjusting for baseline HIV RNA level (P ¼ 0.04, difference in first slope D ¼ À127 Â 10 6 cells/lcomparedwithP ¼ 0.035,D ¼ À134 Â 10 6 cells/l). Moreover, this effect was still significant in the fully adjusted model ( Table 3) .
Effect of baseline HIV RNA load
The CD4þ T-lymphocyte levels at baseline tended to differ according to plasma HIV RNA load (P ¼ 0.07). Indeed, the mean CD4þ T-lymphocyte level was 734 Â 10 6 cells/l (95% CI, 583-884) for those with an HIV RNA load of > 3.3 log 10 copies/ml, 689 Â 10 6 cells/l (95% CI, 546-833) for those with an HIV RNA load between 1.7 and 3.3 log 10 copies/ml and 882 Â 10 6 cells/l (95% CI, 773-991) for those with an undetectable HIV RNA (< 1.7 log 10 copies/ml). The CD4þ Tlymphocyte count decline within the first month after treatment interruption was significantly steeper for the patients with a lower HIV RNA (P < 10 À2 ) achieved under treatment: À23 Â 10 6 cells/l per month (95% CI, À139 to 93), À86 Â 10 6 cells/l (95% CI, À201 to 29) and À238 Â 10 6 cells/l (95% CI, À323 to À153), respectively. During the period after M1, the CD4þ Tlymphocyte slopes significantly decreased in each group (all P < 10 À3 ) but tended to be steeper in patients with the highest HIV RNA load (P ¼ 0.15): À25 Â 10 6 cells/l per month (95% CI, À33 to À16), À16 Â 10 6 cells/l (95% CI, À24 to À7), À14 Â 10 6 cells/l (95% CI, À20 to À7), respectively (Fig. 2b) . In the multivariable model, the effect of HIV RNA load on CD4þ T-lymphocyte kinetics did not remain statistically significant ( Table 3) .
Effect of other baseline factors
Other baseline variables associated with the CD4þ Tlymphocyte level at baseline and during follow-up included the CD8þ T-lymphocyte percentage, the percentage of activated CD4þ DRþ T-lymphocytes, myeloid and lymphoid dendritic cell levels ( Table 3 ). The higher the CD4þ DRþ T-lymphocyte counts and dendritic cells levels (both types) were, the higher was the initial CD4þ T-lymphocyte level (P ¼ 0.03, 0.002 and 0.04, respectively) and the steeper was the CD4þ Tlymphocyte count decline at M1 (P ¼ 0.04, 0.02 and 0.01, respectively). The higher the CD8þ T-lymphocyte percentage was, the lower was the initial CD4þ Tlymphocyte level (P ¼ 0.002) and the blunter was the CD4þ T-lymphocyte count decline at M1 (P ¼ 0.03).
Assuming that mobilization and/or the effect of some cell subsets is correlated to the viral load, we looked at the possible association of these cell subsets with the CD4þ T-lymphocyte count taking into account the HIV RNA level. After adjustment for the baseline HIV RNA level only, the effects of the CD4þ DRþ T-lymphocyte count and myeloid dendritic cells remained unchanged (variation of estimations less than 20%). However, the strength of the effect of the CD8þ T-lymphocyte percentage and the effect of the lymphoid dendritic cells on CD4þ dynamics was decreased ( Table 3 ). In the full multivariable model, the effects which remained significant were: the effect of myeloid dendritic cells on the CD4þ baseline (þ19.5 Â 10 6 cells/l per 10 3 cells/ml higher, P ¼ 0.001) and the first slope (À10.7 Â 10 6 cells/l per month, P ¼ 0.03), the effect of CD4þ DRþ T-lymphocyte count on the first CD4þ slope (À28 Â 10 6 cells/l per month per 1% CD4þ DRþ higher, P ¼ 0.05).
Dynamics of other markers
Plasma HIV RNA load increased from a median of 1.9 log 10 copies/ml (IQR, 1.7-3.3) at baseline to 4.4 log 10 copies/ml (IQR, 3.7-4.8) at M1 and 4.6 (IQR, 4.4-4.9) at M12. The change in HIV RNA load followed a biphasic kinetic similar to that of CD4þ Tlymphocyte as described above with a breakpoint at 1 month. The estimated first month increase was 1.92 log 10 copies/ml per month (95% CI, 1.58-2.26). Thereafter, the HIV RNA load remained stable (0.015 copies/ml per month; 95% CI, À0.0065 to 0.036).
Immunological response to treatment interruption was also explored through modifications in activated cell subsets and dendritic cells ( of 2.8%/month (IQR, 0.20-5.8) and 4.9%/month (IQR, 1.21-11.1), respectively. In the meantime, we observed a median decline in the lymphoid dendritic cell level of À1156 Â 10 6 cells/l per month (IQR, À3853 to 1815).
Joint change in markers
The CD4þ T-lymphocyte count drop observed in the first month following treatment interruption was negatively correlated with the increases in HIV RNA load (r ¼ À0.64, P < 10 À4 ), the CD8þ T-lymphocyte percentage (r ¼ À0.53, P < 10 À4 ), the activated CD8þ DRþ T-lymphocyte percentage (r ¼ À0.56, P < 10 À4 ) and positively correlated with the decline in lymphoid dendritic cells (r ¼ 0.61, P < 10 À4 ).
The decline in lymphoid dendritic cells was itself negatively correlated with the HIV RNA load, the CD8þ T-lymphocyte percentage and the activated CD8þ DRþ T-lymphocyte percentage increases (r ¼ À0.53, r ¼ À0.32, r ¼ À0.47, all P values < 0.05) indicating a link between the number of lymphoid dendritic cells and the viral load which in itself would foster CD8þ T-lymphocytes activation and proliferation.
The first month slopes of HIV RNA load, activated CD4þ DRþ, CD8þ, activated CD8þ DRþ Tlymphocyte percentages and lymphoid dendritic cells did not seem to influence the CD4þ T-lymphocyte count slope significantly after 1 month until month 12 (P ¼ 0.31, 0.40, 0.87, 0.75, 0.97, respectively) which probably represents a situation where all variables are in equilibrium.
Predictors of antiretroviral treatment resumption
Reasons for resumption of antiretroviral treatment by 12 months (n ¼ 8) were: patient's decision (n ¼ 3), occurrence of primo-infection symptoms such as thrombocytopenia (n ¼ 2), rapid decrease in CD4 count below 300 Â 10 6 cells/l (n ¼ 3). The time elapsed until treatment resumption was not significantly different according to HIV RNA load zenith (P ¼ 0.11), CD4þ T-lymphocyte level at M0 (P ¼ 0.12) or HIV RNA at M0 (P ¼ 0.34). The only factor, measured at M0 or before, significantly associated with the time to resumption of the antiretroviral treatment was the CD4þ nadir (P < 10 À3 ). All patients resuming their treatment presented a CD4þ nadir less than 256 Â 10 6 cells/l (first tertile). The Kaplan-Meier plot is shown in Fig. 3 .
Discussion
In this study of the modifications in markers after longterm supervised treatment interruption in chronically HIV-1 infected patients, the change in CD4þ cell count took place in two phases: a first steep decrease in the first month (À142 Â 10 6 cells/l on average), followed by a smooth decline (À17 Â 10 6 cells/l on average) as recently reported in another study [23] . According to baseline CD4þ and HIV RNA levels, our estimations of short term [9, 16, 23] and long term [11, 12, 16] CD4þ changes are similar to other studies as is also the case for HIV RNA [8, 15, 16] .
Interestingly, the second slope of CD4þ T-lymphocyte decline was not correlated with the first and no factor but baseline HIV RNA influenced this second slope. As a consequence, the CD4þ level at the end of the 12-month follow-up was mainly determined by the baseline level and CD4þ modification during the first month. This finding implies that the management of supervised treatment interruption in chronically infected patients should be re-evaluated at 1 month. Furthermore, the decline in CD4þ during the first period may be anticipated, as it was steeper in patients with higher baseline CD4þ and lower HIV RNA levels. This result is in agreement with all previously published studies [9, 11, 13] but one [12] . Moreover, for a given CD4þ level at the time of treatment interruption, the decline was less pronounced in patients with a CD4þ nadir > 350 Â 10 6 cells/l. This effect is much greater than the baseline HIV RNA effect. In fact, patients with lower baseline HIV RNA presented higher baseline CD4þ and steeper short-term decline leading to comparable CD4þ levels at 1 month (Fig. 2b) . However, those with a CD4þ nadir < 350 Â 10 6 cells/l presented similar baseline CD4þ but their short-term decline was greater (À134 Â 10 6 cells/l per month lower). Therefore, when antiretroviral treatment interruption is under consideration, the decision should take into account the CD4þ nadir. Moreover, this result underlines that, in addition to poor CD4þ T-lymphocyte restoration under treatment [24, 25] , the CD4þ decline after treatment interruption is greater in patients having already experienced a more pronounced HIV-CD4þ cell depletion, although this finding is in discrepancy with the study published by Tebas et al. [11] . The importance of the CD4þ nadir on CD4þ T-lymphocyte kinetics after treatment interruption in chronically infected patients has also been reported recently [16] and is likely to reflect the extend of Tlymphocyte repertoire contraction and the difficulty associated with restoring sufficient diversity after HAART initiation. Thus, this information should be integrated in the decision-making process on when to initiate antiretroviral treatment as reaching a value of less than 350 Â 10 6 cells/l may compromise the immune response after subsequent treatment interruption.
One of the aims of our study was to analyse the dynamic and the links potentially existing between several immunological factors particularly in the first month after treatment interruption. As expected, a higher proportion of activated CD4þ T-lymphocytes at baseline was associated with a steeper decrease in the CD4þ T-lymphocyte count, the half-life of such cells being very short [26] . The adjustment for plasma HIV RNA level modified slightly the effect of activated CD4þ T-lymphocyte count reflecting the fact that the activation process is not only mediated through antigenic stimulation [27] . If the activated CD8 DRþ Tlymphocyte count at baseline did not significantly influence the change in CD4þ T-lymphocyte count, the dynamics of the CD8þ DRþ T-lymphocyte count was positively correlated with the viral RNA load increase and the CD4þ T-lymphocyte count decrease as has been reported in patients undergoing antiretroviral treatment [28] . A higher percentage of the CD8þ Tlymphocyte count, as a surrogate marker for the cytotoxic T-lymphocyte antiviral response, was associated with a slower decline in CD4þ T-lymphocyte count and seems to be closely associated with the magnitude of antigenic stimulation measured by the plasma HIV RNA level as its effect on CD4þ Tlymphocyte was not independent. This result is in agreement with those reported in treated patients where the partial antigenic stimulation due to intermittent viremia or persistent low levels of HIV RNA leads to an effective HIV-specific T-cell response [29] . This idea was first described in the context of acute infection [5] . However, some authors have claimed that, although interrupting drug therapy can boost the HIV-specific CD8þ T-cell response, the immune response is limited because of a lack of cytotoxic T-cell diversity, leading to poor control of virus production [30, 31] . In our study, we observed high levels of HIV viral load despite an increase in activated CD8þ T cells. The effects of the different dendritic precursor cells on CD4þ cell count modification were similar. However, this effect seems to be associated partly with HIV RNA load for lymphoid but not for myeloid dendritic cells. The dynamics of each differed: myeloid dendritic cell counts were stable whereas lymphoid dendritic cell counts tended to decrease in association with CD4þ T lymphocytes and in negative correlation with the HIV RNA load slope. In summary, although the influences of baseline myeloid and lymphoid dendritic cells on changes in the CD4þ T-lymphocyte count were comparable, the mechanism through which they are involved is more directly linked to the magnitude of the antigenic stimulation for the lymphoid subset than for myeloid cells. This is in agreement with a negative correlation between lymphoid and HIV RNA load reported elsewhere [32] . Therefore, the decrease in the number of circulating lymphoid dendritic cells with disease progression, which is presumably associated with a decrease in IFN alpha production, should contribute to the lack of HIV virus control [20] . Taken together, these data suggest that lymphoid DC are directly involved in the antiviral response probably through secretion of interferon-alpha and through the specific CD8 T-cell response [33] , whereas myeloid DC seem to be more involved in the dissemination of the infection probably because of their unique DC-Sign expression.
In conclusion, treatment interruption in patients with a CD4þ T-lymphocyte count > 400 Â 10 6 cells/l is followed by a substantial increase in plasma HIV RNA load and a decline in the CD4þ T-lymphocyte count within the first month. Thereafter, there is a nearly steady-state situation in those patients who do not resume their therapy during the 12-month follow-up. The nadir of the CD4þ T-lymphocyte count before treatment interruption exerted a major influence on the level of CD4þ T-lymphocyte count reached after 1 month and therefore on the probability of resuming therapy. This information should become one of the criteria taken into consideration when deciding on treatment interruption, at least in patients above 400 Â 10 6 CD4þ T-lymphocytes/l and should stimulate further research to evaluate strategies allowing at further increase in the CD4þ cell count before interruption. The monitoring of DC cells should be considered on longer follow up to increase our understanding of the complex relationship between the virus and different DC subsets in vivo.
